Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
02 mai 2024 16h05 HE
|
Biomea Fusion, Inc.
Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks,...
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01 mai 2024 16h10 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01 avr. 2024 16h10 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
01 avr. 2024 09h02 HE
|
Biomea Fusion, Inc.
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in...
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
01 avr. 2024 09h00 HE
|
Biomea Fusion, Inc.
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy,...
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
06 mars 2024 03h04 HE
|
Biomea Fusion, Inc.
Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17th Annual ATTD Conference Highlighting BMF-219’s Novel Mechanism of Action in Patients with Type 2...
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01 mars 2024 16h16 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
09 janv. 2024 11h02 HE
|
Biomea Fusion, Inc.
Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1...
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
08 janv. 2024 09h00 HE
|
Biomea Fusion, Inc.
The clinical study, COVALENT-112, has initiated enrollment of adults living with type 1 diabetes in the US and Canada.Eligible patients include those who have been diagnosed with type 1 diabetes for...
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 16h05 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...